UNICREDIT BANK/PUT/ELI LILLY & CO/800/0.1/18.12.24 | Market Closed - Bid/Ask 03:40:13 2024-07-17 pm EDT | After market 03:59:00 pm | |||
| 2.41 EUR | +19.90% |
|
2.635 | +9.34% |
| Current month | -25.83% | ||
| 1 month | -40.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 2.41 | +19.90% |
| 24-07-16 | 2.01 | +2.03% |
| 24-07-15 | 1.97 | -3.43% |
| 24-07-12 | 2.04 | -12.07% |
| 24-07-11 | 2.32 | +5.94% |
Real-time BOERSE MUENCHEN
Last update July 17, 2024 at 03:40 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD5URB |
| ISIN | DE000HD5URB6 |
| Date issued | 2024-05-23 |
| Strike | 800 $ |
| Maturity | 2024-12-18 (154 Days) |
| Parity | 10 : 1 |
| Emission price | 6.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.98 € |
|---|---|
| Lowest since issue | 1.94 € |
| Spread | 0.53 € |
| Spread % | 18.15% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
901.5
USD
Spread / Average Target
-4.26%
- Stock Market
- Warrants
- Warrant
